

Claim

1. An agent for preventing or treating chronic pelvic pain syndrome, which comprises a phosphodiesterase 4 (PDE 4) inhibitor as an active ingredient.

5 2. The agent described in claim 1, wherein the PDE 4 inhibitor is a compound selected from the group consisting of roflumilast, cilomilast, 3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]propanoic acid, 4-(4-{4-[6-(3,4-dimethoxyphenyl)pyridine-2-carbonyl]piperazin-1-yl}phenyl)morpholine, and salts thereof.

3. The agent described in any one of claims 1 and 2, wherein the chronic pelvic pain syndrome is interstitial cystitis.

15 4. Use of a PDE 4 inhibitor for preventing or treating chronic pelvic pain syndrome.

5. Use of a PDE 4 inhibitor for the manufacture of an agent for preventing or treating chronic pelvic pain syndrome.

20 6. The use described in any one of claims 4 and 5, wherein the PDE 4 inhibitor is a compound selected from the group consisting of roflumilast, cilomilast, 3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]propanoic acid, 4-(4-{4-[6-(3,4-dimethoxyphenyl)pyridine-2-carbonyl]piperazin-1-yl}phenyl)morpholine, and salts thereof.

7. The use described in any one of claims 4 to 6, wherein the chronic pelvic pain syndrome is interstitial cystitis.